Quantitative brain MRI analysis for multiple sclerosis and Alzheimer’s-treatment monitoring.
FDA cleared as the first AI-driven MRI solution authorized for safer monitoring of Alzheimer’s treatments; also holds a NICE Medtech Innovation Briefing for multiple sclerosis.
Vendor press release for the FDA authorization.
NICE Medtech Innovation Briefing (a UK health-technology-assessment body) is an independent evaluation signal, alongside a confirmed partnership with the MSAA (a US MS patient association) to expand MRI access.
Partnership confirmed with the MSAA (Multiple Sclerosis Association of America) to expand patient access to MRI monitoring.
As a Belgian company, this is a strong direct benchmark for AI4Hospitals — worth a dedicated deeper dive given local relevance.
This profile is not medical advice or an endorsement. Hospitals should perform their own due diligence (regulatory compliance, GDPR, cybersecurity, integration, local clinical validation). How we evaluate
Every profile documents the precise indication, regulatory status, vendor-supported and independent evidence, real-world deployment, limits and dated sources.
A independent systematic review or prospective multicentre study · B at least one independent peer-reviewed study · C peer-reviewed, vendor-supported · D vendor claims only.
Vendors, authors and clinicians can request a correction. Corrections are dated on the profile.